At IDWeek 2024 in Los Angeles, California, recent updates on mpox (formerly known as monkeypox) were discussed.

Press Release - A drug currently approved for smallpox in the U.S. will undergo clinical trials to treat patients infected by the Mpox viruswho are at risk of severe complications in the Democratic ...

On Friday, Emergent Biosolutions Inc (EBS) stock saw a modest uptick, ending the day at $11.77 which represents a slight increase of $0.77 or 7.00% from the prior close of $11. The stock opened at $10 ...

Avidian Wealth Enterprises LLC cut its stake in shares of Emergent BioSolutions Inc. (NYSE:EBS – Free Report) by 20.4% during ...

The trial will be conducted in the Democratic Republic of the Congo in partnership with Emergent BioSolutions.

Q3 2024 Earnings Call Transcript November 6, 2024 Emergent BioSolutions Inc. beats earnings expectations. Reported EPS is ...

Emergent BioSolutions' Q3 earnings report drives 20% surge in share price, reflecting market optimism. See why award a ...

Wiles is co-chair at lobbying firm Mercury Public Affairs and has represented clients in the tobacco, junk food, insurance, ...

The U.S. overdose crisis and its racial disparities were overlooked in the election, as Black and Indigenous Americans face ...

Emergent Biosolutions ( (EBS) ) has released its Q3 earnings. Here is a breakdown of the information Emergent Biosolutions presented to its ...

Thursday after the company reported strong third-quarter results, lifting retail sentiment. Earnings per share for Q3 came in ...